 | |
| Company type | Subsidiary |
|---|---|
| Nasdaq: CBST | |
| Industry | Pharmaceuticals (Biopharmaceuticals & Biotherapeutics) |
| Founded | 1992 |
| Defunct | 2015 |
| Headquarters | Lexington, Massachusetts |
Key people | Robert J. Perez (president & CEO) |
| Products | Product Pipeline |
| Revenue |  $926.4 million USD (2012) |
| Parent | Merck & Co. |
| Website | www.cubist.com |
Cubist Pharmaceuticals, Inc. was an American biopharmaceutical company that targeted pathogens like MRSA.
.[1] The company employed 638 people, mostly in Lexington, Massachusetts.[2] On 8 December 2014, Merck & Co. acquired Cubist for $102 per share in cash ($8.4 billion).[3]
- ^ Mullin, Emily (26 Aug 2014). "Cubist exec: Challenges mount in antibiotics discovery". Fiercebiotechresearch.com. Retrieved 23 Nov 2014.
- ^ "Cubist Pharmaceuticals Inc. homesite". 2009 Annual Report. Retrieved 20 May 2011.
- ^ Merck to take on superbugs with Cubist Pharma buy. Reuters, 9 December 2014